5th International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplant



The 5th International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplantation and Cellular Therapy (HSCT²) will gather the leaders in the field to update participants on novel mechanisms of relapse that have recently been described and discovered. Participants will benefit from the knowledge of internationally recognized speakers from a diverse multidisciplinary group comprised of basic and translational scientists and clinical investigators.

Learning Objectives:

  • Explain the mechanisms and optimal drug dosing of radio-chemo resistance including new regimens
  • Compare immune escape between leukemia and myeloma, including optimal donor selection and graft source
  • Analyze how the IMPACT FIGARO trial can be applied to individual practice
  • Discuss the variables and considerations in selecting optimal cells for immunotherapy
  • Explain strategies to prevent resistance to CAR T-cell therapy and T-cell exhaustion following relapse for myeloid malignancies and utilize checkpoint blockade to enhance CAR T-cell function
  • Discuss challenges in study designs for relapse prevention in the pursuit of creating improved targeted treatment regimens
  • Describe the mechanisms of relapse microbiota of T-cell trafficking and immune reconstitution
  • Compare how new off-the-shelf cell therapy products affect patients
  • Explain the difference in treatment of relapse between myeloma, lymphoma, myeloid leukemia, and relapse post-CAR T-cell therapy
15.25 AMA PRA Category 1 Credits™

Venue: Grand Hyatt New York


October 8-9, 2021


New York, New York 10017, United States